SEATTLE, June 8 Dendreon Corporation (Nasdaq: DNDN) today announced that management will present at the following investor conferences in June:
The presentations will be audio webcast live and available for replay from Dendreon's website, www.dendreon.com.
Dendreon Corporation is a biotechnology company targeting cancer and transforming lives through the discovery, development, commercialization and manufacturing of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response in a variety of tumor types. Dendreon's first active cellular immunotherapy product, PROVENGEŽ (sipuleucel-T), was approved by the FDA in April 2010 for the treatment of asymptomatic or minimally symptomatic metastatic, castrate-resistant (hormone-refractory) prostate cancer. Dendreon also is developing an orally-available small molecule that targets TRPM8 that could be applicable to multiple types of cancer. The Company is headquartered in Seattle, Washington and is traded on the Nasdaq Global Market under the symbol DNDN. For more information about the Company and its programs, visit www.dendreon.com
Jefferies 2010 Global Life Sciences Conference, New York, NY June 8, 2010 4:00 p.m. ET Needham 9th Annual Health Care Conference, New York, NY June 9, 2010 4:00 p.m. ET Goldman Sachs 31st Annual Global Healthcare Conference, Los Angeles, CA June 16, 2010 6:20 p.m. ET NASDAQ OMX 24th Investor Program, London, GB June 23, 2010 4:30 a.m. ET
SOURCE Dendreon Corporation